Scarica l'app Stockscreener
27.18
1.75%
-0.485
Dopo l'orario di chiusura:
27.18
Maze Therapeutics Inc Borsa (MAZE) Ultime notizie
128,006 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Walleye Capital LLC - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Maze Therapeutics president sells $445,620 in company stock By Investing.com - Investing.com South Africa
Maze Therapeutics president sells $445,620 in company stock - Investing.com
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells $445,680.62 in Stock - MarketBeat
Maze Therapeutics (MAZE) CMO exercises 16,142 options and sells shares under 10b5-1 plan - Stock Titan
Truist Financial Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Announces Target Price $64 - moomoo.com
HC Wainwright Has Positive Estimate for MAZE Q3 Earnings - MarketBeat
Maze Therapeutics adds two directors to board By Investing.com - Investing.com Australia
Maze Therapeutics adds two directors to board - Investing.com
Maze Therapeutics Announces Appointments to Its Board of Directors - The Manila Times
Maze Therapeutics Appoints Paula Johnson and Sophie Kornowski to Board of Directors - Quiver Quantitative
Maze Therapeutics, Inc. Common Stock (NASDAQ: MAZE) Stock Price, News & Analysis - kalkine.ca
Maze Therapeutics (NASDAQ:MAZE) Earns "Buy" Rating from BTIG Research - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
MAZE SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Maze Therapeutics (MAZE) reports $68.9M loss but ends Q2 with $494.9M in cash - Stock Titan
Maze Therapeutics (NASDAQ:MAZE) Announces Earnings Results - MarketBeat
Earnings Flash (MAZE) Maze Therapeutics Posts Q2 Loss $0.76 per Share, vs. FactSet Est of $0.72 Loss - marketscreener.com
Maze Therapeutics Reports Q2 Net Loss Of $44.7 Million - Quiver Quantitative
Maze Therapeutics Q2 net loss widens, misses estimates on higher R&D expenses - TradingView
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - The Manila Times
Press Release: Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - moomoo.com
Jason Coloma: The FTC Killed Our Sanofi Deal. Six Months Later, We Had a Better One. - finance.biggo.com
Maze Therapeutics (MAZE) Earnings Date and Reports 2026 - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Trading Down 6.8%Should You Sell? - MarketBeat
Maze Therapeutics Inc (MAZE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Maze Therapeutics, Inc. (MAZE): Investor Outlook on a Biotech Stock with 119% Potential Upside - DirectorsTalk Interviews
Maze Therapeutics, Inc. (MAZE) CEO Coloma sells 34,501 shares via trusts - Stock Titan
Form 144 Maze Therapeutics For: 3 August By Investing.com - Investing.com Canada
Maze Therapeutics, Inc. $MAZE Stake Reduced by Janus Henderson Group PLC - MarketBeat
MAZE PE Ratio & Valuation, Is MAZE Overvalued - Intellectia AI
Maze Therapeutics, Inc. (MAZE): Analyzing A 126% Potential Upside In Biotech Innovation - DirectorsTalk Interviews
Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares worth $204,859.44 - Bitget
Maze Therapeutics Inc (MAZE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Maze Therapeutics Inc (MAZE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MAZE (NASDAQ: MAZE) investor plans 22,500-share sale after option exercise - Stock Titan
TradingKey - TradingKey
Maze Therapeutics Inc (MAZE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Maze Therapeutics Inc (MAZE) Institutional Confidence - TradingKey
Spruce Street Capital LP Makes New $5.97 Million Investment in Maze Therapeutics, Inc. $MAZE - marketbeat.com
Maze Therapeutics, Inc. Revenue Breakdown – NASDAQ:MAZE - TradingView
Maze Therapeutics Inc (MAZE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Maze Therapeutics Inc (MAZE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Maze Therapeutics Inc (MAZE) Cash Flow - TradingKey
Maze Therapeutics Inc (MAZE) Balance Sheet - TradingKey
MAZE|Maze Therapeutics Inc|Price:27.680| - TradingKey
Maze Therapeutics Inc (MAZE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MAZE|Maze Therapeutics Inc|Price:28.685|Chg%:+1.005 - TradingKey
BABA: Alibaba Group Holding Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Maze Therapeutics (MAZE) Investor presentation Summary - Quartr
Maze Therapeutics (MAZE) Corporate presentation Summary - Quartr
Maze Therapeutics (MAZE) Q4 2025 earnings summary - Quartr
Can Maze Therapeutics, Inc. (MAZE) climb 120.48% to reach the level Wall Street analysts expect? - MSN
Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Maze Therapeutics (MAZE) Stock Looks Fully Priced After A 59% Gain## - Sahm
Maze Therapeutics Advances MZE782 Phase 2 PKU Trial, Setting Up a New Catalyst for MAZE Investors - TipRanks
MAZE Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Stock UptickBook Value Growth - dars.gov.et
MAZE Q1 2026 Earnings: Narrower Loss and Clinical Progress Signal MomentumTangible Book Value - dars.gov.et
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):